Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug interactions that can occur with azole antifungals

Karen Baxter, editor

Alison Marshall, staff editor

Jennifer Sharp, staff editor

Stockley's Drug Interactions

The effect of azole antifungals on selected isoenzymes

A patient who was stable taking carbamazepine for epilepsy, and ranitidine for gastro-oesophageal reflux, required treatment for oesophageal candidiasis following extended treatment with antibacterials. Oral therapy was considered appropriate for this patient.

When considering a suitable antifungal to prescribe several potential areas of concern were considered.

The gastrointestinal absorption of ketoconazole is markedly reduced by ranitidine, and the absorption of itraconazole is reduced (possibly halved) by H2-receptor antagonists. This is because ketoconazole is a poorly soluble base, which must be transformed by the acid in the stomach into the soluble hydrochloride salt.

Ranitidine will decrease gastric acidity so that the dissolution of the ketoconazole and its absorption are reduced. The absorption of itraconazole is also affected by changes in gastric pH, but to a lesser extent.

The most significant interactions caused by the azoles are usually those resulting from inhibition of cytochrome P450 isoenzymes.

The Panel shows the effect various azole antifungals have on selected isoenzymes. Carbamazepine is metabolised by CYP3A4, which the azoles inhibit to varying extents. Therefore the concurrent use of carbamazepine and an azole may lead to carbamazepine toxicity.

Carbamazepine induces CYP3A4, and can also act as an inhibitor of CYP2C19, thus potentially reducing the levels of azoles that are substrates of CYP3A4 and increasing the levels of azoles that are substrates of CYP2C19.

Itraconazole and ketoconazole were not considered to be suitable antifungals, as their absorption would be reduced by ranitidine, and their metabolism also be increased by carbamazepine. Antifungal treatment failure would therefore be a serious possibility. Carbamazepine toxicity may also occur as itraconazole can inhibit carbamazepine metabolism.

Voriconazole was also considered inappropriate, because it is contraindicated with carbamazepine, due to potential interactions.

Fluconazole was selected at a dose of 50mg daily. No initial monitoring was planned since this low dose would not be expected to affect carbamazepine levels. However, the patient was advised to be alert for symptoms of raised carbamazepine levels (which may present as nausea, vomiting, ataxia or drowsiness).

Note that if enzyme inhibition occurs, it is likely to be apparent within two to three days, and persist for a similar time after stopping the fluconazole. Carbamazepine is not known to affect the pharmacokinetics of fluconazole.

This case demonstrates that drugs from the same therapeutic family can demonstrate quite different interaction profiles due to differences both in the way in which they are metabolised and the effect that they have on drug metabolising enzymes.

Although relatively uncommon, drug interactions can also occur as a result of alterations in gastric pH.

Panel: The effect of azole antifungals on selected isoenzymes

 

CYP2C9

CYP2C19

CYP3A4

Fluconazole

Potent inhibitor

Potent inhibitor

Inhibits at doses over 200mg daily

Itraconazole

 

 

Substrate and inhibitor

Ketoconazole

 

 

Substrate and inhibitor

Voriconazole

Substrate and inhibitor

Substrate and inhibitor

Substrate (minor) and inhibitor

Citation: The Pharmaceutical Journal URI: 10006194

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.